Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01788475 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery

A NA study, sponsored by Lahey Clinic.

Terminated
Registry status
NA
Development phase
3
Enrollment target

NCT01788475 is a NA study that was terminated before completion, run by Lahey Clinic. The registered enrollment target is 3 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01788475, a NA study, was terminated before completion, sponsored by Lahey Clinic.

TERMINATED
Registry status
NA
Development phase
3 participants
Enrollment target

Study Summary

Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone prior vitrectomy. The sustained steroid levels may lead to improved central retinal thickness measurements and improved visual acuity.

Interventions

  • DRUG Dexamethasone

Trial Details

FieldValue
Enrollment Target 3 participants
Start Date 2013-02-22
Est. Completion 2014-11-12
Phase NA

Sponsor

Lahey Clinic

43 total trials

What the Registry Record Tells You About NCT01788475

The ClinicalTrials.gov registry entry for NCT01788475 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lahey Clinic, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Dexamethasone is the first listed.

NCT01788475 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01788475 about?

NCT01788475 is a clinical study titled "Safety and Effectiveness of Ozurdex Steroid Implants for DME After Vitrectomy Surgery". Currently medications injected intravitreally in previously vitrectomized eyes have a very short half-life due to enhanced clearance of the drug. The use of the Ozurdex (dexamethasone) implant may allow sustained levels of steroid delivery to patients with diabetic macular edema that have undergone ...

What is the current status of trial NCT01788475?

This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2013-02-22. Estimated completion is 2014-11-12.

What interventions are being tested in trial NCT01788475?

The interventions under investigation include: Dexamethasone (DRUG).

Who is sponsoring clinical trial NCT01788475?

This trial is sponsored by Lahey Clinic, which has 43 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.